The MKNK2 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Burkitt lymphoma Raji B-lymphocyte cell line. This product features targeted disruption of the MKNK2 gene, which encodes the serine/threonine kinase MNK2, a key effector in mitogen- and stress-activated signaling cascades. The polyclonal format provides a heterogeneous loss-of-function model suitable for studying MKNK2-dependent biology without clonal selection artifacts.
Raji cells are suspension-adapted lymphoblastoid B cells established from a patient with Burkitt lymphoma and are positive for Epstein-Barr virus. They serve as a widely used model for B-cell malignancies, exhibiting features of germinal center B cells and providing a reproducible system for investigating lymphoma pathogenesis, signal transduction, and drug responses.
MKNK2 functions downstream of the ERK1/2 and p38 MAP kinases, which are activated by growth factors such as EGF and insulin. Upon phosphorylation, MKNK2 directly phosphorylates the cap-binding protein eIF4E at Ser209, enhancing the translation of mRNAs with structured 5?? untranslated regions??including oncogenic transcripts encoding c-Myc, cyclin D1, and VEGF. This signaling axis integrates inputs from the Ras/Raf/MEK/ERK pathway, with scaffold proteins like JIP1 and the nuclear import factor importin-?? facilitating MKNK2 subcellular localization and substrate access.
In Raji cells, constitutive MAPK pathway activity and high protein synthesis rates drive uncontrolled proliferation and survival. Knockout of MKNK2 is expected to impair phosphorylation of eIF4E, thereby dampening translation of key growth-promoting proteins. This model enables dissection of the MNK2-eIF4E axis in a B-cell malignancy background, providing insights into how cap-dependent translation controls lymphoma cell fitness and potentially revealing vulnerabilities exploitable by MNK-targeted therapies.
Researchers can employ these polyclonal knockout cells to investigate the role of MNK2 in lymphomagenesis, validate drug targets, and screen for MNK2 inhibitors. Typical assays include Western blotting for phospho-eIF4E (Ser209), quantitative RT-PCR analysis of downstream targets (c-Myc, cyclin D1, VEGF), polysome profiling to assess translational efficiency, and functional assessments such as cell viability, apoptosis flow cytometry, and label-free live-cell imaging for proliferation. For further information or technical support, please contact Ascent Research.
